Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR1 | Q92633 | 20/20 | 0.88 |
| ▸ | LPAR3 | Q9UBY5 | 10/20 | 0.88 |
| ▸ | HRH1 | P35367 | 1/20 | 0.57 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.54 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.54 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.54 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | ABCB4 | P21439 | 1/20 | 0.54 |
| ▸ | ABCC2 | Q92887 | 1/20 | 0.54 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.54 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12989973 | 1.00 | LPAR1 (0.88) | LPAR1LPAR3HRH1ABCC3ABCC4 | |
| SCHEMBL12989672 | 0.94 | LPAR1 (1.00) | LPAR1LPAR3HRH1ABCC3ABCC4 | |
| SCHEMBL12989395 | 0.94 | LPAR1 (1.00) | LPAR1LPAR3HRH1ABCC3ABCC4 | |
| SCHEMBL12989627 | 0.93 | LPAR1 (0.98) | LPAR1LPAR3HRH1ABCC3ABCC4 | |
| SCHEMBL12989447 | 0.93 | LPAR1 (0.98) | LPAR1LPAR3HRH1ABCC3ABCC4 | |
| SCHEMBL17077064 | 0.93 | LPAR1 (0.98) | LPAR1LPAR3HRH1ABCC3ABCC4 | |
| SCHEMBL17077063 | 0.93 | LPAR1 (0.98) | LPAR1LPAR3HRH1ABCC3ABCC4 | |
| SCHEMBL12989669 | 0.91 | LPAR1 (0.85) | LPAR1LPAR3HRH1ABCC3ABCC4 | |
| SCHEMBL13195345 | 0.91 | LPAR1 (0.85) | LPAR1LPAR3HRH1ABCC3ABCC4 | |
| SCHEMBL15897121 | 0.91 | LPAR1 (0.73) | LPAR1LPAR3HRH1ABCC3ABCC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140213538-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | INTERMUNE, INC. | 2014-07-31 | — | — | US | disclosed |
| US-20140213538-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | INTERMUNE, INC. | 2014-07-31 | — | — | US | disclosed |
| WO-2014113485-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | INTERMUNE, INC. (US) | 2014-07-24 | — | — | WO | disclosed |
| US-20140200215-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | INTERMUNE, INC. | 2014-07-17 | — | — | US | disclosed |
| US-20140200215-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | INTERMUNE, INC. | 2014-07-17 | — | — | US | disclosed |
| WO-2012138648-A1 | COMPOSITIONS AND METHODS FOR MODULATING LPA RECEPTORS | IRM LLC (BM) | 2012-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140213538-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | LPAR1, LPAR2, LPAR5 | LPAR1 1/4885LPAR3 5/4885HRH1 135/4885 |
| US-20140200215-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | LPAR1, LPAR2, LPAR5 | LPAR1 1/4885LPAR3 5/4885HRH1 135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.